Abstract
To the Editor: In the DESTINY-Breast03 trial, Cortes et al. (Mar. 24 issue)(1) found that trastuzumab deruxtecan therapy prolonged progression-free su......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
